The optimal donor for a patient undergoing reduced-intensity stem cell transplantation remains a human leukocyte antigen (HLA)-matched relative. Alternative donors such as matched unrelated donors (MUDs), mismatched related donors (haploidentical), or unrelated umbilical cord blood (UCB) units have emerged as options as well. The most experience thus far has been with MUD donors, mostly attributed to the development of allele-specific DNA-based HLA-typing methods. The biggest drawback remains the significant delay needed to locate a donor. Haploidentical donors exist for almost all patients, and offer the convenience of a living related donor. However, significant rates of graft-versus-host disease (GVHD) and other toxicities continue to complicate such HLA mismatching. UCB is the most recent option for source of stem cells. Frozen cord blood units can be acquired almost immediately and are able to safely traverse 1 or 2-HLA antigen mismatch barriers. The experience with UCB has been limited by the low cell dose, although recent innovations are attempting to overcome this. In this review, we summarize the current experience and knowledge with alternative donors as stem cell sources for reducedintensity transplantation.
Introduction
The realization of an immunological graft-versus-malignancy (GVM) effect after allogeneic stem cell transplantation has allowed reductions in the intensity of conditioning regimens, as transplantation was no longer reliant on the cytotoxicity of high doses of chemotherapy and/or radiation to eradicate disease. Reduced-intensity conditioning regimens were thought to have the potential to make allogeneic stem cell therapy safer by decreasing acute transplant-related mortality (TRM), thus making transplantation available to many more patients, especially those who are older or have significant comorbidities. Moreover, it was hoped that the establishment of transient donor-host hematopoietic chimerism after reduced-intensity transplantation (RIST) would promote donor-specific tolerance, thereby avoiding a significant graft-versus-host response, and also create a platform to allow administration of immunotherapy in the form of donor lymphocyte infusions (DLIs). [1] [2] [3] [4] Since then, multiple series of patients undergoing RIST for a variety of conditions have been published and have illustrated the feasibility and efficacy of such an approach. Recently, several retrospective analyses comparing RIST to conventional myeloablative transplants have been performed. All of these comparisons have shown that patients undergoing RIST are generally older and have more advanced or active disease at the time of transplant. However, even with these higher risk patients, overall outcomes with RIST in terms of rates of infection, acute graft-versus-host disease (acute GVHD), and overall survival (OS) seem to be comparable to conventional transplantation with a consistent pattern of lower TRM with RIST, but higher rates of relapse. [5] [6] [7] [8] [9] In the absence of randomized-controlled trials, larger observational series with longer follow-up are needed to better define which specific patient populations will benefit the most from undergoing RIST rather than conventional transplantation.
While the optimal allogeneic donor continues to be a fully human leukocyte antigen (HLA)-matched sibling, over 70% of patients who need an allogeneic transplant do not have this option. Thus, there has been a significant experience using alternative donors with many recent series now employing reduced-intensity conditioning regimens. RIST with alternative donors is especially intriguing given the substantial immunological obstacles. While these obstacles may increase rates of graft failure, infection and GVHD, they potentially can stimulate a much more potent GVM effect as well. In this review, we will discuss the current experience of RIST with alternative donors, specifically matched unrelated donors (MUDs), partially matched family member (haploidentical) donors and unrelated partially matched umbilical cord blood (UCB). Admittedly, most of the series summarized below are single-center observational series whose patients differ in many characteristics including patient selection, type and status of malignancy prior to transplantation, conditioning regimen, GVHD prophylaxis and supportive care. Therefore, it is difficult to draw firm conclusions from their comparison. Nevertheless, it is hoped that an appropriate algorithm can be developed for choosing an alternative donor for current patients who will be undergoing RIST.
Matched unrelated donors
The formation of the National Marrow Donor Program (NMDP) spearheaded the use of MUDs for allogeneic transplantation. Currently, the chance of finding a suitably matched donor is between 70 and 80% for most Caucasians, but only approximately 20-30% for most minority patients in the United States. As techniques for HLA typing have transitioned from serological methods to much more precise DNA-based assays, the overall outcomes of MUD transplants have improved, with the most recent series involving conventional MUD transplants showing similar results to matched related donor (MRD) transplants.
In addition, these newer methods have allowed the extension of allele-level typing to all 12 HLA genes although the clinical correlation is unclear. 15, 16 It is hoped that these impressive results will translate into the reduced-intensity setting as well. Indeed, a recent abstract from the Fred Hutchinson Cancer Center in Seattle presented the results of a retrospective analysis showing that there was no significant difference in overall outcomes between RIST MRD and MUD transplants in the age of allele-specific HLA typing. 17 On the basis of extensive experience and proven track record of MUD transplants, enthusiasm for and clinical trials studying RIST with MUDs has grown tremendously. Some selected series of RIST MUD transplants are shown in Table 2 .
Much of the experience in MUD RIST in the United States has been reported from the Fred Hutchinson Cancer Center. Investigators have focused on a conditioning regimen composed of fludarabine with 2 Gy of total body irradiation (TBI) and posttransplant GVHD prophylaxis with cyclosporine and mycophenolate mofetil (MMF). Niederwieser et al. 18 initially reported a series of 52 patients in which donors were HLA-matched in 71% of cases and mismatched in 29% of cases with typing done by serological methods. Durable donor chimerism was seen in 88% of these patients and acute GVHD was observed in 63% (42% grade II and 21% grades III and IV). With a median followup of 19 months, 35% of patients were alive and 25% were in complete remission. A later series of 89 patients using a similar treatment plan with donor grafts from 10/10 HLA MUDs was also reported. Typing was performed by intermediate resolution DNA techniques, and a subsequent retrospective analysis showed that the majority (65/85) of patients were allele level matched with only one patient having more than one mismatched HLA class I antigen. Durable engraftment was observed in 85% of peripheral blood stem cell (PBSC) recipients and 56% of bone marrow recipients. The incidence of grade II GVHD was 48%, but only 10% of patients had grade III and IV GVHD. One-year non-relapse mortality was 16%, progressionfree survival (PFS) was 38%, and OS was 52%. 19 Subsequently, changes were made in an attempt to increase the durable engraftment rate including using strictly PBSCs and increasing post-transplant MMF to three times daily rather than twice daily. In a recent series of 103 patients, durable engraftment was 95%; however, outcomes including GVHD, PFS and OS were similar to previous trials. 20 Current trials are aimed at decreasing the rates of both acute and chronic GVHD by using different agents for prophylaxis. Retrospective analyses from the above series has shown that, when compared to MRD RIST, patients who have undergone MUD RIST have slower immune reconstitution, especially in the first 100 days after transplant, 21 and also have longer periods of blood and platelet transfusion dependency. 22 Investigators from several centers in the United Kingdom have focused their efforts in MUD RIST by using alemtuzumab for in vivo T-cell depletion. Recently, a series of 47 patients who received transplants from matched (n ¼ 27) and mismatched (n ¼ 20) unrelated donors with HLA typing performed by serological methods was published from several centers. Conditioning consisted of fludarabine and melphalan with alemtuzumab. Post-transplant GVHD prophylaxis was with cyclosporine alone. 100-day TRM was 15%, and 85% of patients achieved full donor chimerism with only three patients developing grade III and IV acute GVHD. With follow-up of approximately 1 year, PFS was 76% and OS was 62%. 23 A Swedish study retrospectively analyzed the outcomes of 137 patients who underwent RIST between 4/99 and 2/05, comparing outcomes of those with MRDs (n ¼ 63) to those with MUDs (n ¼ 74). Patient characteristics were similar between the two groups with the exceptions that donor age was significantly older in the MRD group (median age 52 versus 36), and many more patients in the MUD group received antithymocyte globulin (ATG) (100% versus 46%). Typing for HLA class I and II molecules was performed by analysis of allele level PCR single-stranded polymorphisms. Rates of graft failure and acute GVHD were similar between the two groups, but chronic GVHD was higher in the MRD group, believed most likely to be due to older donor age. As expected, TRM was significantly increased in the MUD group (40 versus 16%), and relapserelated deaths were higher in the MRD group, leaving OS similar between the two groups. One major caveat to this study was that about 30-40% of these patients had underlying solid tumors, making the results somewhat less generalizable to the majority of patients for whom RIST is now considered. 24 A small Japanese experience was reported on 20 patients who were transplanted between 2000 and 2002. Typing was carried out with high-resolution DNA methods and all donors were fully (6/6) HLA matched. Conditioning was nucleoside analogue based (either fludarabine or cladribine) with the addition of either ATG or TBI (4 or 8 Gy). Post-transplant GVHD prophylaxis was cyclosporine7methotrexate. Nineteen patients achieved primary engraftment, and five died within the first 100 days due to transplant-related complications. A total of 7 patients developed acute GVHD and 7 of 13 who survived past 100 days developed chronic GVHD. Estimated OS at 1-year was 35% although median follow-up was only 5.5 months. 25 Another Japanese series has been reported describing 27 patients from multiple institutions who were treated with a myriad of conditioning regimens. While 1-year OS and PFS probabilities of 42 and 30% were observed, a high incidence of non-relapse mortality mainly due to infections associated with acute GVHD was seen. 26 The preliminary results of a large Italian series evaluating 118 patients between the ages of 45 and 65 years were published recently. Patients were either conditioned with the combination of melphalan, alemtuzumab, fludarabine and 200 cGy of TBI or with thiotepa, cyclophosphamide and ATG. Graft failure was observed in only 9% of their patients, TRM was 20%, and grade II-IV acute GVHD was seen in 29%. With limited follow-up, the incidence of extensive chronic GVHD was only 7%, relapserelated death was 18%, and OS was 57%. This led the authors to conclude that MUD RIST was a feasible approach for the population studied, but they noted that only 30% of their original cohort of patients underwent transplant, with many succumbing to disease progression before a suitably matched donor could be found. 27 As the success of unrelated transplants has grown, several disease-specific series have been published. Recently, a series of 21 patients with chronic myeloid leukemia (15 in chronic phase) undergoing RIST from HLA 10/10 allele-matched donors was described from Seattle. Conditioning was again with fludarabine and 2 Gy of TBI with cyclosporine and MMF given as posttransplant immunosuppression. Initial donor engraftment was observed in 18 patients, but only 11 achieved sustained engraftment. Graft failure was usually followed by autologous reconstitution and subsequent relapse. Six of these 11 patients experienced grade II GVHD, while three experienced grade III disease. Seven of the 11 who had long-term engraftment were able to remain in complete cytogenetic remission at the time of publication. The 100-day and 1-year mortality rates for those who had sustained engraftment were 0 and 11%, respectively. Due to such a high rate of graft failure, their future efforts in the chronic myeloid leukemia population undergoing RIST will now focus on using strictly PBSCs and giving more intense immunosuppression prior to transplant. 28 Their experience also illustrates that high rates of graft rejection will commonly be observed in patients with a high leukemia burden and suggests that more myeloablative conditioning regimens should be considered to aid in engraftment in this setting.
Limited follow-up of separate series of patients undergoing MUD RIST have been recently published for other diseases as well. An European Group for Blood and Marrow Transplantation (EBMT) registry study analyzed 214 patients with CLL who underwent either conventional or reduced-intensity transplant and found no significant differences in outcomes. 29 A separate EBMT registry study detailed 67 patients with MDS or secondary acute myeloid leukemia, showing a 33% 2-year disease-free survival probability, and a 58% rate of relapse. 30 A British series reported on older patients with MDS, many of who had other comorbidities, and illustrated the feasibility of an alemtuzumabbased regimen. 31 An analysis was performed by the CIBMTR of patients who underwent MUD hematopoietic stem cell transplantation for Hodgkin's lymphoma, and showed no significant differences in outcomes when comparing myeloablative transplants to RIST. 32 Investigators from MD Anderson have presented the results of their series of RIST for Hodgkin's lymphoma and showed promising results with a 2-year PFS of 32% in a heavily pretreated population with no differences in outcomes between related and unrelated donors. 33 Investigators from Seattle have illustrated the potential efficacy of MUD RIST in multiple myeloma, showing a 2-year PFS of 41% in their cohort of 24 poor-risk patients, with half of their patients receiving a planned tandem approach of autologous transplant followed by RIST. 34 Much enthusiasm has especially arisen for patients with more indolent diseases, as it is thought that successful GVM requires time to develop, and more aggressive diseases may relapse or progress quickly.
While MUD RIST has experienced significant growth, many questions and obstacles remain. The biggest downside in using a MUD is the delay in locating a donor. This is a significant problem for two reasons: (1) many patients may experience relapse or progression of disease while waiting, and (2) the immunological GVM effect takes at least several months to cultivate. This issue was illustrated in the Italian series where only 1/3 of their initial cohort eventually underwent RIST with the majority of the remaining patients experiencing relapse of their disease. 27 Moreover, a German study has recently found that identification of one fully compatible unrelated donor usually required confirmatory typing of at least 2-5 potentially matched donors. 35 With faster exchange of information, it is hoped that this delay can be minimized, although it will continue to be somewhat unavoidable and certainly longer than what is needed to identify haploidentical or UCB donors.
An additional question to be answered is exactly how much matching is necessary, given that allele-specific HLA-typing methods allow for exact matching for up to all 12 HLA class I and class II antigens. While a fully MUD is currently favored over a haploidentical or UCB donor, it is unclear at what degree of mismatch the other sources become preferred. Likewise, it is unclear if a fully matched MUD donor is preferred over a single antigen-mismatched-related donor. While longer follow-up and larger series will provide additional information, questions like these will be difficult to resolve given the heterogeneity of protocols, the differences in patient selection and the lack of prospective randomized trials.
While the success of RIST varies with the type and biology of disease, it is also clear that disease status prior to transplant is a powerful predictor of disease-free and OS, suggesting that GVM is most effective in a minimal disease state, although relapse rates are certainly significant in this subset as well. Future research will continue to define better patient selection for RIST, including using more effective ways to achieve a minimal disease state prior to RIST. In addition, investigation will also pursue how to best harness GVM by enhancing overall immune reconstitution, using different combinations or length of posttransplant GVHD prophylaxis, and augmentation via vaccinebased approaches. 36 One intriguing study from the University of Michigan has actually shown a much better disease-free survival rate with RIST from unrelated donors compared to related donors in patients with MDS or acute myeloid leukemia using a conditioning regimen composed of fludarabine, busulfan and total lymphoid irradiation. Believed to benefit from a more potent GVM effect stimulated in the unrelated setting, patients from both groups had comparable rates of GVHD and TRM. 37 Longer follow-up and larger numbers are obviously needed to substantiate these data, but as infection and GVHD are better controlled, the powerful promise of using an unrelated donor may eventually be realized. While there is still much room for improvement, a MUD currently appears to be the first alternative for patients in whom RIST is indicated and who do not have a related donor.
Partially matched related (haploidentical) donors
Partially matched related (haploidentical) donors refer to related donors who share one haplotype and who are mismatched for 1, 2 or 3 HLA antigens. Whereas less than 30% of patients who need a transplant will have a MRD, greater than 90% will have a haploidentical donor. Using a haploidentical donor has the advantages of the immediate availability of a related donor, the potential of a much stronger GVM effect due to greater HLA disparity, and the regular access to donor lymphocytes for delayed DLI. 38 The downsides of crossing such major HLA barriers are a significant rate of graft rejection, an increased risk of GVHD and poor or delayed immune reconstitution after transplant. [39] [40] [41] While the use of reduced-intensity conditioning regimens has ameliorated many of the immediate organ toxicities of transplantation, selective ex vivo manipulations of the mismatched graft have been used to attempt to deal with these significant immunological barriers. The eventual goal of these methods is to be able to selectively exclude cells responsible for causing GVHD while preserving those essential for GVM and normal immune function. 42 Selected series of haploidentical RIST are collected in Table 3 .
On the basis of murine models showing that GVM effects from DLI are more potent in mixed hematopoietic chimeras, 43 investigators at the Massachusetts General Hospital have designed a protocol to achieve mixed lymphohematopoietic chimerism as a platform for giving adoptive immunotherapy using delayed DLI. Several adjustments were made for the initial high rates of graft failure and acute GVHD and have resulted in a conditioning regimen of cyclophosphamide, fludarabine, thymic radiation and MEDI-507 (a monoclonal anti-CD2 antibody) with cyclosporine used for post-transplant GVHD prophylaxis. In addition, prior to infusion, donor PBSCs are Tcell-depleted through ex vivo positive selection for CD34 þ cells. With this latest regimen, mixed chimerism has been reliably achieved allowing later delivery of DLI with significant responses observed in some cases, 44 but too few numbers to report conclusively. One unexpected observation was that durable antitumor responses were observed in some patients despite loss of the donor graft, raising the possibility that a hostspecific antitumor response had been stimulated. 45 This phenomenon was also reported by another group, 46 and further research into the underlying mechanism is ongoing.
Researchers at Johns Hopkins University have focused their efforts on using post-transplant doses of high-dose cyclophosphamide (50 mg kg À1 ) as a way to decrease rates of both graft rejection and acute GVHD following non-T-cell depleted (TCD) haploidentical RIST. In 2002, the results of their initial phase I experience were published. Out of a cohort of 13 patients, 8 achieved sustained donor engraftment, 6 developed acute GVHD, and 6 were alive at a median follow-up of 191 days (5 in complete remission). 47 In 2004, Fuchs et al. 48 presented an updated series involving 56 patients with a variety of advanced hematological malignancies treated with fludarabine, cyclophosphamide and TBI (2 Gy) as conditioning, and tacrolimus, MMF and cyclophosphamide (either 1 or 2 doses) as prophylaxis for GVHD. Graft rejection occurred in only nine patients, and grade II-IV GVHD occurred in 43% of patients receiving two doses of cyclophosphamide, and 78% of patients receiving one dose. At a median follow-up of 172 days, 21 patients were alive and disease-free.
Investigators at Duke University recently published the results of their haploidentical RIST experience, which utilizes alemtuzumab as a method of in vivo T-cell depletion. Their conditioning regimen consists of fludarabine, cyclophosphamide and alemtuzumab with MMF7cyclosporine as posttransplant GVHD prophylaxis. A total of 49 patients with hematological malignancies or marrow failure syndromes were treated, with 94% achieving successful donor engraftment. Remarkably, 75% of patients with hematological malignancies were able to achieve a complete remission with acute treatment-related mortality reported of 10.2% and a severe GVHD incidence at 8%. OS was 31% at 1 year for all patients and 63% for the 19 patients who were considered standard risk patients. 49 A Japanese experience included 26 patients who underwent conditioning with fludarabine, busulfan and ATG followed by a two or three HLA-antigen mismatched non-TCD haploidentical PBSC transplant. Post-transplant GVHD prophylaxis consisted of tacrolimus and corticosteroids with a low threshold for starting treatment with other agents. All patients except one achieved full donor chimerism. Ten patients developed GVHD (five with grade I and five with grade II) and, at a median follow-up of 664 days, 15 patients were alive and in complete remission. 50 To improve outcomes of haploidentical RIST, several groups have suggested refinements to current methods of donor selection including taking advantage of killer immunoglobulin receptor ligand mismatching and feto-maternal chimerism in hopes of reducing GVHD and augmenting GVM. Regarding killer immunoglobulin receptor ligand mismatching, results have been unclear in the unrelated [51] [52] [53] [54] and conventional haploidentical transplant settings. 55 In haploidentical RIST, an analysis of patients treated at Johns Hopkins showed that killer immunoglobulin receptor ligand incompatibility in the GVH direction was associated with a prolonged time to relapse and improved OS. 56 Certainly, longer follow-up and larger experiences are awaited. The concept of feto-maternal chimerism presumes that fetal exposure to non-inherited maternal antigens (NIMA) during gestation can lead to lasting microchimerism resulting in the induction of tolerance to NIMA, which could lead to decreased rates of both graft rejection and GVHD. A previous IBMTR analysis had suggested that a transplant from a NIMA-mismatched sibling resulted in significantly reduced rates of acute GVHD when compared to a transplant from a paternal antigen mismatched sibling. 57 A heterogeneous series from Japan of 35 patients transplanted based on detectable microchimerism of NIMA-mismatched siblings illustrated the feasibility of such an approach but still had a significant rate (56%) of grade II-IV acute GVHD. 58 Two small series have also reported on this approach with reduced-intensity conditioning regimens, 59 ,60 but more experience and longer follow-up are clearly needed. These mixed results in series with limited number of patients suggest that more data are needed before either of these refinements become criteria for donor selection.
Many questions remain regarding reduced-intensity haploidentical transplantation. The most compelling reasons to continue investigation in this area are the ease and availability of a related donor and the potentially powerful GVM effect. However, it remains to be seen if infection, graft failure and GVHD can all be safely avoided to result in long-term improvements in survival. Selective depletion of subsets of cells through either in vivo or ex vivo positive or negative selection based on cell-surface markers has emerged as one way to accomplish this, and as shown above, several groups are pursuing this approach. Further selection among available donors based on killer immunoglobulin receptor ligand matching and feto-maternal chimerism are interesting concepts, but neither has been conclusively determined to be of any further benefit. In looking ahead, the biggest obstacles to the growth of haploidentical RIST may not be its intrinsic complications, but rather the impressive outcomes with transplants using MUDs and the significant progress and enthusiasm for using UCB.
Umbilical cord blood
UCB transplantation has relatively recently been established as a viable source of hematopoietic stem cells for allogeneic transplantation. As of August 2005, more than 3700 cord blood transplants had been performed worldwide with over half of the recipients being adults. 61 As with other stem cell sources, UCB has its own specific advantages and disadvantages. Cord blood differs from PBSCs and bone marrow in three major ways: (1) the speed of availability, (2) the number of stem cells received and (3) the HLA matching or histocompatibility requirements between donor and recipient. In contrast to the time needed to acquire stem cells from a living adult donor (anywhere from a few days to several weeks), cord blood units can be immediately released from a cord blood bank if needed, thereby significantly reducing the waiting period. Admittedly, it is not known if this reduction in time to transplant has a meaningful effect on outcomes as it could potentially end up selecting for patients whose diseases are destined to relapse quickly. While UCB has become readily accepted as a standard donor source in the pediatric population, the low stem cell dose in each cord blood unit has somewhat limited its application in adults, although current protocols are finding ways to overcome this (see below). Lastly, in terms of histocompatibility, while 6/6 HLA matching is usually preferred for unrelated donors and at least 5/6 for related donors, 4/6 HLA matches are fully acceptable for UCB transplants given the intrinsic immaturity of UCB stem cells. 62 Because of this acceptable mismatching, UCB transplants hold great promise for many patients who do not have a suitably HLA-matched adult donor.
While randomized studies comparing different donor sources will most likely never be done, several large retrospective series evaluating myeloablative single UCB transplants have shown encouraging results with overall outcomes comparable to historical control groups of MUD transplants. [63] [64] [65] However, early experience has also revealed that the low stem cell dose and significantly prolonged period of immunosuppression afterwards have led to an increased risk for complications such as opportunistic infections, viral reactivation and a prolonged need for transfusions. In an effort to decrease these risks, several approaches have been utilized, including co-infusion of multiple UCB units, 66 ex vivo expansion of UCB progenitor cells, 67 and co-infusion of haploidentical PBSCs. 68 Furthermore, to expand the eligibility of UCB transplantation, protocols with reduced-intensity conditioning regimens have been developed and have built upon the lessons learned from the early myeloablative experience. Selected series of recent UCB RIST are detailed in Table 4 .
Researchers at the Massachusetts General Hospital and Dana Farber Cancer Institute treated 21 patients with a variety of underlying hematological malignancies. Their conditioning regimen consisted of fludarabine, melphalan and ATG with post-transplant GVHD prophylaxis with cyclosporine and MMF. Attempting to overcome the low cell dose, UCB grafts were composed of two UCB units, each of which were at least 4/6 HLA matches with both the donor and with each other while having a combined minimum cell dose of 3.7 Â 10 7 nucleated cells per kg. Median time to absolute neutrophil count (ANC) of 4500 ml À1 was 20 days and median time to platelet transfusion independence was 41 days. Early graft failure occurred in two patients, and both patients were able to receive a second UCB transplant. Acute GVHD occurred in 40% of patients and 1-year disease-free survival was 67%. 69 A more recent cohort of 18 patients with limited follow-up but promising preliminary results was treated with the same conditioning regimen but with sirolimus and tacrolimus as post-transplant GVHD prophylaxis. 70 The University of Minnesota Group has had the most experience with UCB RIST in the United States. The results of their first 43 transplants were published in 2003, showing encouraging results as seen in Table 4 . 71 In their most recent cohort of patients, slight alterations in their protocol were made, including the use of double cord units to achieve a higher Table 4 Major series of umbilical cord blood RIST These series did not specify between limited or extensive stage chronic GVHD.
f Duration of follow-up was not specified in this series.
g TRM is reported here as non-relapse mortality without a time period specified.
h Rates of DFS and OS are 2-year rates in this series.
Reduced-intensity transplants using alternative donors Y-B Chen and TR Spitzer minimal cell dose, using cyclophosphamide rather than busulfan, and giving ATG to patients who had undergone less than two cycles of chemotherapy in the 3 months prior to transplant. A total of 110 patients were treated with a conditioning regimen of fludarabine, a single dose of cyclophosphamide, and 2 Gy of TBI, and then infused with one or two UCB units (at least 4/6 HLA matched) with a median cell dose infused of 3.6 Â 10 7 nucleated cells per kg. GVHD prophylaxis consisted of cyclosporine and MMF. Sustained donor engraftment was eventually observed in 92% of patients with median days to neutrophil recovery of 12 days. The cumulative incidence of grade III-IV GVHD was 22%, and 3-year OS and PFS probabilities were 45 and 38%, respectively. 72 A recent smaller series from France used a similar regimen and demonstrated comparable results. 73 Researchers at Duke University, after noting significant rates of graft failure in their early cohort of 13 patients, 74 added 2 Gy of TBI to a conditioning regimen of fludarabine, cyclophosphamide and ATG in a more recent series of 12 patients. Posttransplant GVHD prophylaxis for all patients consisted of cyclosporine and MMF. In addition, the minimum donor cell dose was increased from 1 Â 10 7 to 3 Â 10 7 nucleated cells per kg, and use of a second cord was allowed to achieve this count in their second population. Comparison of the results between these two groups showed that the addition of 2 Gy of TBI and the increase in the minimum required cell dose resulted not only in a doubling in sustained donor engraftments rates (83 versus 41%), but also produced an increase in 100-day TRM (30 versus 15%) resulting in no significant difference in the 1-year diseasefree survival rates (17 versus 15%). 75 The most impressive results in myeloablative UCB transplantation have come from Japan. Thought to be due to significantly less haplotype heterogeneity, patients in Japan have consistently had better engraftment, less GVHD and better overall outcomes, even surpassing their experience with MUDs. 65 Whether the UCB RIST experience will parallel this success awaits long-term follow-up. Miyakoshi et al. 76 presented the results of 107 patients transplanted in Tokyo who received a conditioning regimen consisting of fludarbine, melphalan and 4 Gy of TBI and post-transplant GVHD prophylaxis with either cyclosporine or tacrolimus. Primary graft failure was seen in only 8% of patients with median neutrophil recovery of 20 days and median platelet recovery at 46 days. The incidence of grade II-IV GVHD was 39.8% and 100-day non-relapse mortality was 51.6%. With a median follow-up of 14 months, OS was 29.9%. Several other smaller series from Japan have also been reported, [77] [78] [79] [80] and long-term follow-up is awaited.
One lesson, which has emerged from these early series of UCB RIST, is that viral reactivation remains a significant cause of morbidity post-transplant. In a large retrospective analysis of 166 Japanese patients who underwent UCB RIST, reactivation of cytomegalovirus occurred in 70% of patients with actual disease developing in 19%. 81 Brunstein et al. 82 found a significantly increased risk of Epstein-Barr virus-related complications, specifically post-transplant related lymphoproliferative disorder, in UCB RIST patients who had received ATG as part of their conditioning regimen. Two recent series concluded that UCB transplantation was a significant risk factor for HHV-6 reactivation, 83, 84 but further analysis is needed to conclude if this holds true for patients receiving reducedintensity conditioning regimens as well. Nevertheless, close monitoring for reactivation of Epstein-Barr virus, cytomegalovirus and HHV-6 with DNA-based assays should be strongly considered in the immediate post-transplant period after UCB RIST.
While longer follow-up of these early series of UCB RIST is awaited, several retrospective analyses have raised questions on how to best choose UCB units. As mentioned above, the UCB cell dose infused has been shown to correlate with the rate of successful engraftment, time to neutrophil and platelet recovery and overall outcomes. This seems to hold true for both myeloablative and reduced-intensity transplants and the currently accepted minimum thresholds for UCB units are 1.7 Â 10 5 CD34 þ cells per kg or 2.5 Â 10 7 nucleated cells per kg with many protocols requiring even higher doses. 61 Among the several proposed methods to compensate for low cell doses in adult transplantation, the infusion of multiple units has emerged as the most accepted and has been adopted in many RIST protocols as shown above. Interestingly, in separate retrospective analyses, investigators from the University of Minnesota have preliminarily shown that, when compared to single UCB transplants, the use of multiple cords not only increased the risk of acute GVHD in a large heterogeneous group of patients, 85 but also significantly decreased the rate of relapse in a series of acute myeloid leukemia patients. 86 Whether this holds true for patients undergoing RIST and whether it will influence survival in the long run remains to be seen.
One of the biggest advantages of using UCB is the acceptable HLA disparity between cord units and the recipient. However, even though a significant degree of mismatching is acceptable, it still appears that closer matching portends a better prognosis. Barker et al. 87 presented an analysis of 608 patients who received conventional UCB transplants and showed that HLA disparity correlated with higher TRM, even in the absence of GVHD. Japanese investigators evaluated 156 patients who underwent UCB RIST and found that degree of HLA mismatching was significantly associated with primary graft failure. 88 Given what is currently known, it is difficult to know how to prioritize cell dose versus HLA disparity when faced with a choice between several UCB units. Furthermore, when faced with UCB units with suboptimal characteristics, it is unclear when to use other alternative donor sources such as a living haploidentical donor.
As is the case for most issues in allogeneic hematopoietic stem cell transplantation, efforts to define the place of UCB RIST has been hampered by the lack of prospective randomizedcontrolled trials. However, limited retrospective analyses have provided encouraging early results. Tashiro et al. 89 presented a study comparing 30 patients who underwent conventional UCB transplantation with 22 who underwent UCB RIST showing similar rates of engraftment, time to neutrophil recovery, and GVHD, although follow-up duration was short. Brunstein et al. reviewed 63 patients with acute myeloid leukemia who underwent RIST followed either by UCB (n ¼ 43) or HLA-matched sibling PBSC (n ¼ 21) infusion. All patients received the same conditioning and GVHD prophylaxis regimens. Multivariate analysis showed that only disease risk group was prognostic of relapse or OS, and outcomes between donor types were not significantly different. 90 Researchers in Japan reviewed medical records of 62 patients with either MDS or acute myeloid leukemia who received RIST between 2001 and 2005 from related PBSC (n ¼ 20), unrelated BM (n ¼ 19) and UCB (n ¼ 23) donors. While expected differences were seen in HLA disparities, cell dose infused, conditioning regimens, GVHD prophylaxis and timing of engraftment, overall outcomes in terms of incidence of acute and chronic GVHD, relapse rates, and OS were similar among all three groups. 91 While these series of UCB RIST have illustrated the feasibility of such an approach and an encouraging disease-free survival rate, follow-up for the majority of these patients is still short.
It remains to be seen whether a reduced-intensity conditioning regimen will have any detrimental impact on rates of graft failure or relapse of disease in the long term. For now, it appears that the best available method to compensate for the inherently low cell dose of UCB is through the infusion of multiple UCB units, and this has been readily incorporated into RIST protocols with encouraging preliminary results. In addition, it is still unknown who the best population is to receive a UCB RIST although series of patients with the same underlying diagnosis have recently been presented. Majhail et al. 92 have published a small series showing comparable outcomes in patients with advanced Hodgkin's lymphoma who received RIST from either an MRD or UCB donor. In addition, Barker et al. presented the early results of 16 patients with indolent non-Hodgkin's lymphoma who underwent UCB RIST. At 1-year, PFS was 63% with longer follow-up eagerly awaited. Lastly, one additional disadvantage of using UCB is that DLIs in the context of graft failure or relapse of disease are not possible, and this issue may become more important in the future as the role and efficacy of DLI is better developed.
Summary
While much progress in RIST with alternative donors has been made in the last several years, the field is still very much in its infancy. Each of the three options of alternative donors has inherent advantages and disadvantages. RIST from MUDs has had the most experience thus far, mainly through the growth of unrelated donor banks and the emergence of HLA allele level typing methods. The primary limitations of using a MUD donor are the delay in locating an unrelated donor and the lower chance of finding a suitably matched donor for most minority patients. Haploidentical donors have the advantages of availability and convenience in collecting both initial stem cells and future DLIs as well as imparting a potentially more potent GVM effect, but are complicated by more graft rejection, GVHD and poorer immune reconstitution given the significant HLA disparity between patients and donors. UCB is the most recent option and is attractive because of its immediate availability from donor banks and the relative laxity in HLA matching requirements. Its main disadvantages are the low stem cell dose in each UCB unit, the longer time to engraftment and transfusion independence and no possibility of future DLI.
As RIST with MUD donors have had the most experience and best record of success, MUD donors are currently the first option for patients who lack a suitably MRD. Traditionally, one HLAantigen disparate related donors have been preferred over unrelated donors as well, but with allelic level HLA typing, this has recently come into question. If a search through unrelated adult registries does not yield a suitably MUD, typing of other relatives and a search for potentially compatible UCB units should be undertaken. In the absence of a MUD donor, enrollment on a clinical trial studying either UCB or haploidentical RIST is very reasonable. In the absence of participation in a clinical trial, an UCB donor seems to be emerging as the best option after a MUD donor given the recent growth in experience and encouraging early results. Using a haploidentical donor for RIST currently stands as the third option after MUD and UCB donors, although the most recent series discussed above report encouraging progress. One important challenge ahead will be to define if this general algorithm can be applied to all disease states, or if certain patients in different situations may do better with a specific type of donor.
While most modern regimens seem to have overcome early issues of graft failure, the persistent obstacles, which are common among RIST with any alternative donor include significant rates of infection, GVHD and relapse of disease. One focus of current research is improving immune reconstitution after transplant in hopes of preventing more infections. Other trials are investigating more targeted combination therapy in the prophylaxis of GVHD, in hopes of better prevention and less broad immunosuppression. Lastly, it is evident that transplant is most effective when patients are in a minimal disease state; thus, better patient selection and non-transplant therapies prior to transplant will improve outcomes. As these supportive measures improve, it is hoped that GVM can also be exploited more effectively to realize the potential of RIST. While a MRD for hematopoietic stem cell transplantation remains the preferred choice, it is not unreasonable to believe that, for certain patients who will require a significant GVM effect, alternative donors may one day become the stem cell source of choice.
